Best pharmaceutical companies in Foster City, CA

SciClone Pharmaceuticals, Inc. (SciClone ) is a global specialty pharmaceutical company. It has a product portfolio of therapies for cancer and infectious diseases. SciClone has in-licensed two products that are part of this international commercial growth strategy, DC Bead and ondansetron RapidFilm. Its DC Bead product candidate is a treatment for liver cancer, which is approved in 40 countries worldwide, including Europe and the United States. Ondansetron RapidFilm is an oral thin film formulation of ondansetron used to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy and surgery. SCV-07 is being developed for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck and for the treatment of hepatitis C virus (HCV). Thymalfasin is being developed in an ongoing clinical trial for improvement of Influenza A (H1N1) vaccination.

CAPNIA is a private company developing novel therapeutic products using its proprietary medical gas delivery system. We are targeting a number of chronic diseases treatable with topical application of well understood, safe and effective gas compounds. Our first product is entering Phase IIb clinical trials for the treatment of acute migraines and related symptoms. 28 million Americans and over 240 million people worldwide suffer from this debilitating condition.

Gilead Palo Alto, Inc. develops and commercializes small molecule drugs for the treatment of cardiovascular diseases. It develops advances in molecular biology and genetics to identify mechanisms of cardiovascular diseases and targets for drug discovery. The company offers Ranexa (ranolazine extended-release tablets), which is used for the treatment of chronic angina; and Lexiscan (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI). Its products under clinical development comprise Tecadenoson, which is in Phase III clinical trials product for the potential reduction of rapid heart rate during acute atrial arrhythmias, and in Phase II clinical trials for acute atrial fibrillation; Adentri, a Phase III clinical studies product for heart failure; CVT-6883, a Phase I clinical trial product to treat cardiopulmonary diseases; and CVT-3619, a Phase I clinical studies drug for diabetes/metabolic syndrome. The company s products under preclinical trials include Tecadenoson for atrial fibrillation; CVT-10,216 to treat alcohol addicted patients; Late I for the treatment of coronary artery disease; A2A antagonist for chemical dependence; ABCA1/ApoA-I to treat atherosclerosis; and Drug-Eluting Stent Program for the treatment of restenosis. The company has collaborative partnerships with Biogen Idec Inc.; Astellas Pharma, Inc.; Menarini Group; and Roche Palo Alto LLC. Gilead Palo Alto, Inc. was formerly known as CV Therapeutics, Inc. and changed its name to Gilead Palo Alto, Inc. in January 2009. The company was incorporated in 1990 and is based in Foster City, California. As of April 14, 2009, Gilead Palo Alto, Inc. operates as a subsidiary of Gilead Sciences Inc.